A new manuscript focused on data needs for the development of vaccines and monoclonal antibodies (mAbs) to effectively address AMR was just published during World Antimicrobial Awareness Week (WAAW), by PrIMAVeRa consortium partners at the University of Geneva.
November 2024
The study, titled “Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies” highlights key research priorities to better inform strategies for tackling AMR in Europe.
The investigators conducted systematic reviews and an expert elicitation using the Delphi method to identify key drug-resistant pathogens and patient groups that require urgent attention in future research. Priority pathogens identified include third-generation cephalosporin-resistant Klebsiella pneumoniae for patients diagnosed with bloodstream infections, third-generation cephalosporin-resistant Escherichia coli for urinary tract infections, and methicillin-resistant Staphylococcus aureus for surgical-site infections.
These recommendations will also help to improve future AMR burden study estimates.
The publication emphasises the importance of evidence-based decision-making in combating AMR and improving public health outcomes.
The PrIMAVeRa consortium congratulates the authors and look forward to continuing the battle against AMR.
Read the publication:
Hassoun-Kheir Nasreen, Guedes Mariana, Arieti Fabiana, Pezzani Maria Diletta, Gladstone Beryl Primrose, Robotham Julie V, Pouwels Koen B, Kingston Rhys, Carmeli Yehuda, Cassini Alessandro, Cecchini Michele, Drobniewski Francis, Frost Isabel, Geurtsen Jeroen, Kronenberg Andreas, Htay Mila Nu Nu, Paul Mical, Rocha-Pereira Nuno, Rodríguez-Baño Jesús, Scudeller Luigia, Stewardson Andrew J, Tacconelli Evelina, Harbarth Stephan, Vella Venanzio, de Kraker Marlieke EA. Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies. Euro Surveill. 2024;29(47):pii=2400212. https://doi.org/10.2807/1560-7917.ES.2024.29.47.2400212
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the author's view, and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
Comments